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Decrease of Morbidity and Cost of Care
with Prophylactic Cranial Irradiation for
Non-small Cell Lung Cancer
Champ, C.E., Ohri, N., Werner-Wasik, M.
Department of Radiation Oncology, Thomas Jefferson University Hospitals, Philadelphia, PA

Purpose

Conclusion

While several studies analyze the incidence of brain metastases
in patients with non-small cell lung cancer (NSCLC) treated with
prophylactic cranial irradiation (PCI), there is little data available on
how this treatment can affect medical cost and morbidity. Our goal
was to analyze those issues patients encounter secondary to brain
metastases, often in the final months of their lives, and to support the
hypothesis of economic benefit and cost effectiveness resulting from
the use of PCI in this population.

Brain metastases commonly occur in Stage III, NSCLC and cause
significant morbidity and financial burden from hospital stays,
imaging exams, and surgical interventions. Since RTOG 0214 showed
that PCI reduced the incidence of brain metastases in these patients
from 18 to 7.7% at 1 year, if used routinely, it could potentially reduce
the cost in this patient population while decreasing morbidity and
optimizing resource utilization.

Method and Materials
We identified 13 consecutive patients with stage III NSCLC, who
developed brain metastases at 5-20 months after initial primary
tumor diagnosis, with an average of 13.5 months. All patients but four
died, at an average of 8 months from diagnosis of brain metastases.
We retrospectively analyzed the number of brain MRI and CT scans,
hospital visits with length of stay, craniotomies, whole brain radiation
and stereotactic radiation for each patient, at our hospital only, with
accompanying estimated cost. These numbers were used to assess
cost effectiveness and morbidities caused by the exams, surgeries,
and hospitalizations.

Results
Eight patients had craniotomies, with 2 patients undergoing multiple
operations. The average number of MRIs was 7, with one patient
having 19. There was an average of 4 CT scans per patient. All patients
had brain metastases related hospitalizations, with an average of 13.4
days per patient. All patients received whole brain radiation therapy.
Finally, 7 patients received stereotactic radiosurgical boost for their
brain lesions, with two receiving multiple treatments. As a result,
in the final 8 months of their lives, our patients spent an average
of 13 days in the hospital, with over 10 imaging scans performed in
this time period, and a median of one craniotomy. During those 8
months, an estimate of minimal cost from our institution (excluding
outside hospitalizations) on average was $57,455.
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